About Ascelia
Ascelia is a publicly listed company based in Malmo (Sweden) founded in 2000. It operates as a developer of orphan drugs for treatment and diagnostics solutions. Ascelia has raised $6.92 million across 2 funding rounds. Ascelia offers products and services including Orviglance and Oncoral. Its focus areas include Life Sciences, Rare Diseases, In Vitro Diagnostic Tests and Oncology. Its legal entity is Ascelia Pharma AB. Its competitors include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen and 2 more; 7 of its 7 listed competitors have raised funding.
Company details
Ascelia was founded in 2000 in Malmo, Sweden, within the pharmaceutical sector. Drug candidates targeting diseases with unmet clinical needs are developed, focusing on orphan indications. Operations center on clinical-stage products, including Mangoral, a contrast agent prepared for phase 3 trials to identify liver metastases via MRI, and Oncoral, an oral chemotherapeutic in phase 2 for advanced gastric cancer.
- Headquarters Malmo, Sweden
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ascelia.com
- Social LinkedIn
- Legal Name Ascelia Pharma Ab
- Net Profit-$8.28 M (USD)4.72as on Dec 31, 2025
- EBITDA-$7.95 M (USD)-9.01as on Dec 31, 2025
- Total Equity Funding$6.92M (USD)
in 2 rounds
- Latest Funding Round$23.38M (USD), Post-IPO
Mar 2021
Products & Services of Ascelia
Ascelia offers a comprehensive portfolio of products and services, including Orviglance and Oncoral.
Imaging agent for detecting liver metastases in cancer
Treatment option for gastric cancer patients
Funding Insights of Ascelia
Ascelia has successfully raised a total of $6.92M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $23.38 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.92M
- Total Rounds 2
- Last Round Post-IPO — $23.38M
- First Round $6.92M
(May 2018)
All 2 funding rounds of Ascelia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $23.38M | Post-IPO | – | – | – |
| May 2018 | $6.92M | Series A | – | – | – |
People of Ascelia
10 people are tracked at Ascelia (8 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Nadilka Hettiarachchige | Global Director Medical Affairs | Leadership |
Marie Källström | VP, Regulatory Affairs & QA | Leadership |
Julie Waras Brogren | Deputy CEO (cfo, Cco, Business Development), Ascelia Pharma (nasdaq: Ace) | Leadership |
Magnus Corfitzen | CEO | Leadership |
Andreas Norlin | Chief Scientific Officer | Leadership |
Déspina Georgiadou Hedin | Chief Financial Officer | Leadership |
Carin Linde | VP, Pharmaceutical Development & Supply and IT | Leadership |
Jennie Wilborgsson | VP, Clinical Development | Leadership |
Christina Sundberg | Development Project Manager | Team |
Delphine Biro | Executive Assistant | Team |
Complete people profiles for Ascelia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ascelia
Ascelia is a publicly listed company on the OMXSTO with ticker symbol ACE in Sweden, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Mar 2019
- Listed onNASDAQ OMX: ACE
- Listed entityAscelia Pharma AB
- Exchange sectorHealth technology
- ISINSE0010573113
- Share price0.61 SEK (-9.63% on the day) · 2026-10-14
- Market capitalisation90,136,428.00 SEK
- EPS (diluted, trailing year)-0.48 SEK
- Volume (last session)506,831
Financials of Ascelia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -76.2M SEK | -73.2M SEK |
| 2024 | – | -80.0M SEK | -67.2M SEK |
| 2023 | – | -109.3M SEK | -110.4M SEK |
| 2022 | – | -131.2M SEK | -146.6M SEK |
| 2021 | – | -125.9M SEK | -136.9M SEK |
Detailed financial statements for Ascelia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ascelia
4 dated milestones of Ascelia across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Ascelia is founded.
- Funding First funding round of $6.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $23.4M.
Competitors of Ascelia
Ascelia has 7 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Ascelia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ascelia
The website of Ascelia (ascelia.com) receives about 6K visits a month.
- Monthly visits6K
▼ 20.3% vs previous month
Top companies in Rare Diseases
10 companies that operate in the same segment as Ascelia (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ascelia
Complete news archive for Ascelia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascelia
Ascelia was founded in 2000 and raised its 1st funding round 18 years after it was founded.
Ascelia is headquartered in Malmo, Sweden.
Ascelia is a funded company, having raised a total of $6.92M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.92M, raised on May 2018.
Ascelia was founded in 2000 in Malmo, Sweden, within the pharmaceutical sector. Drug candidates targeting diseases with unmet clinical needs are developed, focusing on orphan indications. Operations center on clinical-stage products, including Mangoral, a contrast agent prepared for phase 3 trials to identify liver metastases via MRI, and Oncoral, an oral chemotherapeutic in phase 2 for advanced gastric cancer.
Ascelia's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Ascelia offers Orviglance and Oncoral.
Yes, Ascelia is publicly traded on OMXSTO under the ticker symbol ACE.
Ascelia operates through Ascelia Pharma Ab.